Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.35 |
| ▸ | FEN1 | P39748 | 5/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658381 | 0.81 | MPO (0.39) | GCKKMT2APDPK1 | |
| SCHEMBL28515229 | 0.77 | EPAS1 (0.44) | EPAS1 | |
| SCHEMBL30194063 | 0.77 | EPAS1 (0.44) | EPAS1 | |
| SCHEMBL31210714 | 0.76 | PDPK1 (0.44) | PDPK1 | |
| SCHEMBL190746 | 0.76 | GCK (0.67) | GCKEPAS1MEN1KMT2A | |
| SCHEMBL972681 | 0.73 | GCK (0.46) | GCKEPAS1SLC6A2 | |
| SCHEMBL190710 | 0.71 | GCK (0.39) | GCKEPAS1MEN1KMT2A | |
| SCHEMBL191325 | 0.70 | GCK (0.54) | GCKMEN1KMT2A | |
| SCHEMBL1257119 | 0.69 | — | — | |
| SCHEMBL17872367 | 0.69 | FEN1 (0.47) | ALOX5APFEN1PDPK1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | GCK 2/4885EPAS1 712/4885MEN1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.